Abstract
Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Volume: 11 Issue: 1
Author(s): Wei-Hua Yan
Affiliation:
Keywords: HLA-G, malignancies, diagnosis, prognosis, immunotherapy, b2-microglobulin, trogocytosis, cytotrophoblasts, cutaneous melanoma, glioblastoma multiforme, hydatiform moles
Abstract: Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells (NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
Export Options
About this article
Cite this article as:
Yan Wei-Hua, HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187153011794982059
DOI https://dx.doi.org/10.2174/187153011794982059 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry A Role for Milk Proteins and their Peptides in Cancer Prevention
Current Pharmaceutical Design Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Coupling of Conjugating Enzymes and Efflux Transporters: Impact on Bioavailability and Drug Interactions
Current Drug Metabolism Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents The Sour Taste-Modifying Protein (Miraculin), Tyrosinase Inhibitors and Antioxidants from Synsepalum dulcificum
Current Nutrition & Food Science Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets Epidermal Cell Proliferation in Calorie-Restricted Aging Rats
Current Aging Science Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Mucoadhesive Vaginal Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics
CNS & Neurological Disorders - Drug Targets Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Synthesis and Applications of Nanoflowers
Recent Patents on Nanotechnology Cranberry for Urinary Tract Infection: From Bench to Bedside
Current Topics in Medicinal Chemistry